Is Psychedelic Therapy Ready for FDA Approval?
Robin Carhart-Harris, a consciousness and psychedelics researcher at UCSF, discusses the current state of psychedelic therapy research, including the FDA's denial of MDMA-assisted therapy approval, the critical importance of therapeutic context, and key risk factors and contraindications for psychedelic treatment.
Summary
Robin Carhart-Harris of UCSF discusses the state of psychedelic research in a wide-ranging interview. He describes the field as having passed through a hype cycle following Michael Pollan's 2018 book, with a subsequent market correction and the significant setback of the FDA denying Lykos/MAPS approval for MDMA-assisted therapy for PTSD. Despite this, he remains optimistic, noting that publication rates and trial quality are at all-time highs, and that Compass Pathways' psilocybin therapy for treatment-resistant depression is likely the closest to FDA approval.
Carhart-Harris argues that psychedelic therapy is fundamentally a combination treatment — the drug induces a neuroplastic state, and the therapeutic context ('set and setting') shapes what is done with that state. He is currently running controlled experiments manipulating context variables such as music, aesthetic environment, and quality of psychological support to empirically test this assumption. He describes the therapy model as largely non-directive during dosing sessions, with meaningful psychological support occurring in preparation and integration phases.
The interview addresses significant safety concerns, particularly around recovered memories. Carhart-Harris acknowledges that cases of alleged recovered memories have occurred at multiple major research sites, including his own. He warns that psychedelics could become 'hypnosis on steroids' if therapists impose their beliefs on vulnerable patients, and describes a specific case where a patient emerged with an uncertain recovered memory of attempted harm by a parent, leading to clinical worsening.
On contraindications, Carhart-Harris notes that clinical trials systematically screen out individuals with histories of psychotic illness or personality disorders. Data from real-world psychedelic use shows that people with personality disorder histories are four times more likely to experience worsening outcomes, while those with schizophrenia histories are twice as likely. He acknowledges this creates a 'cherry-picking' problem in clinical research. He also distinguishes MDMA from classic psychedelics like psilocybin and LSD, describing it as less unpredictable and more of a 'heart opener' than a 'head opener,' making it more compatible with conventional talk therapy formats.
Key Insights
- Carhart-Harris argues that the 'secret source' of psychedelic therapy is a combination of the drug inducing neural plasticity and the therapeutic context shaping that plastic state — he considers the two inseparable, and is currently running controlled experiments to empirically test how much context variables like music, aesthetics, and psychological support actually matter.
- Carhart-Harris explains that the FDA denied MDMA-assisted therapy approval partly because it was framed as a combination treatment ('MDMA-assisted therapy'), which the FDA said fell outside its remit as a drug-approval body — a framing problem he says Compass Pathways is deliberately avoiding with its psilocybin submission.
- Carhart-Harris warns that psychedelics could become 'hypnosis on steroids' when it comes to recovered memories, noting that cases of alleged recovered memories have occurred at his own trials and at Hopkins, and that therapists who impose their beliefs on vulnerable patients during sessions represent a serious and growing risk, including potential legal exploitation.
- Carhart-Harris reports that in real-world psychedelic use data, people with a history of personality disorder diagnosis were four times more likely to fall into the worst-outcome group, and that their decline was delayed — they showed slight short-term improvement before experiencing a clinically meaningful worsening further out — while those with schizophrenia history were twice as likely to have poor outcomes.
- Carhart-Harris acknowledges that clinical trials systematically screen out individuals with personality disorders and psychotic illness, and concedes this means the field has 'arguably and fairly cherrypicked' a more resilient population, making the published positive results less generalizable to the broader population that might seek psychedelic therapy.
Topics
Transcript
[0:00] The secret source of this treatment is in that combination of a drug action that opens up the mind, makes it more plastic. By simple logic, you have a plastic state. You got to do the right thing with that. You know, it's more shapable. So, shape it right. >> I am here with Robin Carheart Harris. Robin, thanks for joining me again. >> Thanks for having me on. >> So, um, remind people where you are, um, doing your research on psychedelics. >> I'm at the University of California, San Francisco. I have my lab there. And [0:30] >> and what's the focus of your research at this point? >> It's consciousness science and how it's encoded in…
Full transcript available for MurmurCast members
Sign Up to AccessMore from Sam Harris
Anne Applebaum: The Corruption Most Americans Don't See
Anne Applebaum discusses how U.S. foreign policy under Trump has become a tool for corruption, involving ideological revolutionaries seeking to dismantle institutions and align with far-right European movements. She explains that Europe, facing Russian threats and U.S. unreliability, is rearming itself while Ukraine demonstrates surprising military capabilities in an intensifying war.
A Father With Cancer Asks Sam Harris a Heartbreaking Question
Sam Harris responds to a 37-year-old man with brain cancer asking whether it's ethical to have a second child given his 10-year life expectancy. Harris agrees with Peter Singer's perspective that having another child is ethically permissible, arguing that a 10-year horizon is fundamentally different from terminal illness, and that all people live with radical uncertainty about their lifespans.
5 Seconds vs. 5 Days
The speaker argues that the duration of emotional states like anger is far more significant than their occurrence, comparing it to the difference between briefly noticing a clenched fist versus being unaware of it for extended periods. They use this metaphor to explain how meditation awareness allows people to recognize and release negative mental states quickly, whereas lack of meditation leaves people hostage to their thoughts.
It's a Coin Toss Whether AI Takes Over
Ryan Greenblatt, Chief Scientist at Redwood Research, discusses AI safety risks and estimates a 50-60% chance of misaligned AI takeover on the current development trajectory. He explains his path to AI safety work through effective altruism, defines key concepts like AGI and ASI, and addresses why AI companies continue rapid development despite these risks despite high-stakes probabilities.
Why Is Nick Fuentes So Compelling?
A speaker discusses the psychological tension of finding Nick Fuentes compelling despite his antisemitic views, attributing this to his strong media skills and charisma. The conversation draws parallels to Trump, exploring how entertaining personalities can attract audiences despite holding objectionable beliefs and political commitments.